The massive dilutive offering relative to market cap signals acute capital needs. Monitor for shareholder vote on warrant exercise authorization (required within 90 days) and any clinical milestone announcements that would trigger warrant exercisability. The stock is likely to face significant downward pressure from the dilutive overhang and potential near-term selling by investors who received shares at a discount.
Price Chart
Executive Summary
Decoy Therapeutics entered into a securities purchase agreement to raise approximately $3.5 million through a private placement of common shares and warrants (Series A, B, and C) at $5.91 per share. The warrants are exercisable upon achieving specific clinical milestones (Phase 1 CTA filing, Phase 2a trial initiation, and Phase 2a primary endpoint) and require shareholder approval. The offering is highly dilutive relative to the company's $3 million market cap, and the funds are earmarked for general corporate purposes including SEC filing catch-up and working capital.
Key Financial Metrics
Key Facts
- Private placement raises approximately $3,500,002.47 in gross proceeds
- Per share purchase price of $5.91
- Investors receive Series A, B, and C warrants exercisable for 100% of the shares purchased each, at $5.91 per share
- Warrant exercisability is contingent on clinical milestones (Phase 1 CTA filing, Phase 2a trial initiation, Phase 2a primary endpoint) and shareholder approval
- Company must seek shareholder approval within 90 days of closing, and every 90 days thereafter until obtained
- Proceeds to be used for general corporate purposes, including filing outstanding SEC reports and working capital
- Company market cap is approximately $3 million, making the offering size roughly 117% of market cap
- Placement agent is Curvature Securities LLC
- Lock-up agreements required from executive officers and directors
Financial Impact
Approximately $3.5 million gross proceeds, representing roughly 117% of the company's $3 million market cap. The offering includes warrants for up to 300% of the shares sold, creating massive potential dilution.
Risk Factors
- Extreme dilution: warrants for up to 300% of shares sold could massively increase share count if exercised
- Shareholder approval may not be obtained, potentially triggering repeated special meetings and uncertainty
- Clinical milestones required for warrant exercisability are uncertain and may not be achieved
- Company may need additional capital beyond this raise, given the small absolute amount relative to typical biotech burn rates
- Nasdaq listing compliance risk given micro-cap status and potential stock price decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-286737 |
| Document: dcoy-ex4_2.htm | 0001193125-26-286737 |
| Document: dcoy-ex4_3.htm | 0001193125-26-286737 |
| Document: dcoy-ex4_4.htm | 0001193125-26-286737 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | EFFECT | $1.17 $0.9100 | ▼ −22.22% | ▼ −22.08% | $0.9200 (−21.37%) |
Oct 7, 2026 19d ago | S-1 | $1.52 $1.23 | ▲ +19.08% | ▲ +18.80% | $0.9200 (+39.47%) |
Sep 23, 2026 4w ago | 8-K | $3.11 $1.86 | ▲ +40.35% | ▲ +39.94% | $0.9200 (+70.42%) |
Aug 4, 2026 11w ago | DEFA14A | $4.19 $3.60 | ▼ −14.08% | ▼ −14.43% | $0.9200 (−78.04%) |
Jul 20, 2026 14w ago | EFFECT | $5.31 $3.74 | ▼ −29.50% | ▼ −29.10% | $0.9200 (−82.66%) |
Jun 29, 2026 17w ago | 8-K | $9.59 $7.25 | ▲ +24.40% | ▲ +25.79% | $0.9200 (+90.41%) |
Jun 25, 2026 17w ago | EFFECT | $5.92 $7.62 | ▲ +28.76% | ▲ +27.20% | $0.9200 (−84.45%) |
Jun 4, 2026 20w ago | DEFA14A | $6.71 $5.90 | ▼ −12.07% | ▼ −9.52% | $0.9200 (−86.29%) |
Apr 30, 2026 25w ago | 10-K/A | $6.05 $6.01 | ▼ −0.66% | ▼ −2.39% | $0.9200 (−84.79%) |
Apr 2, 2026 29w ago | 8-K | $5.80 $5.84 | ▲ +0.69% | ▼ −2.93% | $0.9200 (−84.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers